

10/524869

DT05 Rec'd PCT/PTO 11 FEB 2005 #3

EXPRESS MAIL LABEL NO. EV380370836US

Date Mailed: February 11, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Clarence-Smith, *et al.*

Appl. No. Not Yet Assigned

Filed: February 11, 2005

For: DERIVATIVES OF GLYCINERGIC
R (+) -2-AMINO-3-HYDROXYPROPANOIC
ACID

Attorney Docket Number:
05933.0016.PCUS00

Information Disclosure Statement

MAIL STOP PCT (DO/EO/US)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- 1. This Information Disclosure Statement is being filed;
 - ☐ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
 - b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - ☐ c. Before the mailing date of a first Office Action on the merits;
 - ☐ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- ☐ 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement

was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or

- ☐ c. Please charge 180.00 to deposit account 08-3038 for payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a

patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.


- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 05933.0016.PCUS00.

Respectfully submitted,

Date: February 11, 2005



Viola T. Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP

2941 Fairview Park Drive

Box 7

Falls Church, VA 22042

Tel: (650) 463-8181

Fax: (650) 463-8400

D105 rec'd PCT/PTO 11 FEB 2005

**INFORMATION DISCLOSURE
CITATION****PTO-1449**

ATTY. DOCKET NO.

05933.0016.PCUS00

SERIAL NO.

Not yet Assigned

APPLICANT : CLARENCE-SMITH, et al.

FILING DATE: 02/11/05

GROUP: Not yet Assigned

U.S. PATENT DOCUMENTS

EX'R INITIAL	PATENT NO.	DATE MM-YYYY	NAME	CLASS	SUBCLASS	FILING DATE
	5,837,730	11/17/1998	Daniel C. Javitt			
	5,854,286	12/29/1998	Daniel C. Javitt et al.			
	6,228,875	05/08/2001	Guochuna Tsai et al.			

FOREIGN PATENT DOCUMENTS

EX'R INITIAL	PATENT NO.	DATE MM-YYYY	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP0528172	02/24/1993	EP				
	W098/03472	01/29/1998	WO				
	PCT/FR03/02447 (Search Report)	02/27/04	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EX'R INITIAL	DOCUMENT
	Robert Haner et al. ; "155. Preparation and C-Alkylation of Enantiomerically Pure S-Phenyl Aziridinecarbothioates. On the Structure of Small-Ring Ester Lithium Enolates"; HELVETICA CHIMICA ACTA, Vol. 70, no. 7, 1987, pages 1676-1693
	Susan E. Gibson et al. ; "Synthesis of Conformationally constrained Phenylalanine Analogues Via 7-, 8- and 9-endo Heck Cyclisations"; JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1., NO. 4, 1997, PAGES 447-455
	CHEMICAL ABSTRACTS, vol. 76, no. 7, 14 February 1972 (1972-02-14) Columbus, Ohio, US ; abstract no. 34561T, A. BALOG et al. ; "Peptides. XE. Use of Serine N-Protected with beta-Dicarbonyl compounds in Peptide Synthesis" page 347; column 1; XP002239529 abstract -& " FORMULAS C6H10N8-C9H13BrPb" CHEMICAL ABSTRACTS (9 TH COLLECTIVE INDEX), Vol. 76-85, 1972-1976, page 2920F XP002239528 Columbus Ohio, US page 2920F, column 3, line 84-line 85

EXAMINER:**DATE CONSIDERED:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).